PMCB LTD

What PMCB LTD does

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) is a clinical-stage biotechnology company developing cellular therapies for cancer, diabetes, and malignant ascites. Its core platform is Cell-in-a-Box®, a proprietary cellulose-based live-cell encapsulation technology in which genetically engineered human cells are enclosed in bio-inert, pinhead-sized capsules with pores calibrated to admit small-molecule prodrugs while excluding immune cells and preventing cell escape. Each capsule holds approximately 20,000 modified cells and the system has demonstrated in-body stability and activity for at least two years, with the Master Cell Bank stable for 36+ months in liquid-nitrogen vapor phase storage.

The company's lead product candidate, CypCaps™, encapsulates HEK293 cells engineered to express cytochrome P450 2B1, which converts the inactive prodrug ifosfamide into its active cancer-killing form at the tumor site when capsules are implanted in the blood supply adjacent to a locally advanced, inoperable pancreatic tumor (LAPC). The same encapsulation platform underpins a preclinical diabetes program using Melligen cells engineered to release insulin in response to blood glucose (a "bio-artificial pancreas") and a malignant ascites program reusing the CypCaps cell line in the peritoneal cavity. CypCaps has FDA Orphan Drug Designation for LAPC, but the IND is currently under an FDA clinical hold; the company reports ~90% of FDA hold-lifting requests have been addressed as of late 2022, with a two-phase pig study among the remaining items.

PharmaCyte is pre-revenue with no commercialized products and 1–10 employees. Its intended revenue model is licensing and royalties following FDA approval, with products administered in the near term through qualified clinical trial sites and hospital settings where interventional radiologists implant capsules and oncologists administer ifosfamide. The company maintains a multi-party operational ecosystem spanning Austrianova (GMP manufacturing), Biologics Consulting (regulatory), Imaging Endpoints (imaging core lab), Inno Biologics (cell cloning), and Fisher BioServices (cryostorage), and in 2021 raised approximately $90M through two public offerings concurrent with its Nasdaq uplist, leaving ~$85M in cash as of April 30, 2022. Following a 2022 cooperation agreement with activist Iroquois Capital, the company reconstituted its board with five new independent directors, appointed a new interim CEO, authorized a $10M share repurchase, and formed a Business Review Committee to evaluate strategic alternatives.

Name

PMCB LTD

Legal name

PharmaCyte Biotech, Inc.

Website

https://pharmacyte.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

PharmaCyte Biotech (NASDAQ: PMCB) is a clinical-stage biotechnology company developing cellular therapies for pancreatic cancer, diabetes, and malignant ascites using its proprietary Cell-in-a-Box® live-cell encapsulation platform; it is pre-revenue, under an FDA clinical hold, and exploring strategic alternatives following a 2022 activist-led board reconstitution.

Ownership category

akta.pro rank

Product category

Cellular Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Cellular therapy development
• Live-cell encapsulation
• Pancreatic cancer treatment
• Diabetes cell therapy
• Biopharmaceutical research

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Cellular Therapy Development and Commercialization: PharmaCyte is a clinical-stage biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites. The company does not yet have commercialized products and is pre-revenue, working through FDA clinical trial requirements to bring its therapeutic candidates to market.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

PharmaCyte Biotech is a clinical-stage biotechnology company that develops cellular therapies for cancer, diabetes, and malignant ascites using its proprietary Cell-in-a-Box® live-cell encapsulation technology. The platform encapsulates genetically engineered human cells within bio-inert cellulose capsules, enabling targeted therapy delivery such as CypCaps™, which converts the chemotherapy prodrug ifosfamide into its active form at pancreatic tumor sites using cytochrome P450-expressing cells. The company also develops encapsulated Melligen cells as a bio-artificial pancreas for diabetes treatment and encapsulated cells for malignant ascites in the peritoneal cavity.

Product overview

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer, diabetes, and malignant ascites. The company's core technology is the Cell-in-a-Box® live-cell encapsulation platform, which uses bio-inert cellulose capsules to enclose genetically engineered human cells. For pancreatic cancer, the CypCaps™ product encapsulates cytochrome P450-expressing cells that activate chemotherapy drug ifosfamide at tumor sites. The diabetes program uses encapsulated Melligen cells to produce insulin in response to blood sugar levels. The company also has a malignant ascites treatment program using the same encapsulated cell technology. All programs are in various stages of clinical or preclinical development, with the company working to address FDA clinical hold requirements for its pancreatic cancer IND.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell-in-a-Box® Proprietary cellulose-based live-cell encapsulation technology platform that encapsulates genetically engineered human cells within bio-inert cellulose (cotton-derived) capsules for targeted therapy delivery. Capsule pores are sized to allow small-molecule drugs to enter while keeping immune system cells out and encapsulated cells in. Capsules are about the size of a pinhead, each containing approximately 20,000 cells, and have demonstrated safety and durability for at least two years in the body.
• CypCaps™

Quantifiable outcome

• One-third normal dose of ifosfamide required due to targeted activation at tumor site
• +5 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• CORE IRminorImplementation/ SI/ Consulting Partner · 11 July 2022Investor relations contact for media and investor inquiries
• Biologics ConsultingcoreImplementation/ SI/ Consulting Partner · 14 February 2022Full-service regulatory and product development consulting firm retained to perform regulatory 'Gap Analysis' and assist with IND submission to FDA; provides fresh regulatory perspective with personnel having extensive FDA experience
• Imaging Endpoints Research and Core LabcoreStrategic or Co-development Partner · 5 October 2015Imaging core lab partner for clinical trials; provides centralized radiology interpretations, advanced imaging analysis, real-time scan evaluation, and expertise in pancreas cancer imaging for Phase 2b trial design
• University of Technology Sydney (UTS)coreStrategic or Co-development Partner · 23 June 2015Partnership to co-develop preclinical diabetes treatment using Cell-in-a-Box technology with Melligen cells engineered to produce insulin; collaboration with Prof. Ann Simpson for insulin-dependent diabetes therapy development
• Inno Biologics Sdn. Bhd.minorStrategic or Co-development Partner · 4 November 2013Contracted for initial cell cloning for future Phase 3 clinical trials; cGMP-compliant facilities for cell production
• Fisher BioServices, Inc.minorStrategic or Co-development Partner · 10 September 2013Contracted for long-term storage of cells required for future Phase 3 and other cancer clinical trials
• Austrianova (SG Austria)coreStrategic or Co-development PartnerManufacturing partner for CypCaps production; provides Master Drug File information to FDA on manufacturing process improvements; manufactures empty capsules for biocompatibility studies; critical partner for GMP production and quality control of Cell-in-a-Box encapsulated cells

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Anavex Life Sciences: Small-cap clinical-stage biotech focused on neurological and rare diseases; comparable to PharmaCyte in size, capital structure, and clinical-stage profile, though with different therapeutic targets.
• BrainStorm Cell Therapeutics: Clinical-stage cell therapy company developing autologous cell therapies for neurodegenerative and other diseases; comparable platform-stage cell therapy company with similar regulatory and clinical execution profile.
• Novocure: Commercial-stage oncology company using a device-based tumor-treating fields platform; comparable to PharmaCyte in pursuing mechanism-driven solid tumor therapies (notably pancreatic cancer) and pursuing FDA-regulated approval pathways.
• Capricor Therapeutics: Clinical-stage biotechnology company developing cell-derived extracellular vesicle and cell therapy candidates; comparable as a small-cap, clinical-stage biotech leveraging cell-based therapeutics with a multi-indication pipeline.
• Mustang Bio: Clinical-stage cell and gene therapy company developing engineered cell therapies for oncology; directly comparable to PharmaCyte's cell-therapy platform approach and similar stage/size profile as a small-cap clinical biotech.
• Onconova Therapeutics: Clinical-stage oncology biotech developing small-molecule and cellular therapeutics; overlaps with PharmaCyte in the small-cap clinical-stage oncology space and shares board ties (Jack Stover as prior CEO).
• Pluristem Therapeutics: Clinical-stage cell therapy company developing placenta-derived cell therapies; comparable to PharmaCyte as a small-cap, clinical-stage cell therapy developer with a proprietary platform applied across multiple indications.
• Vericel Corporation: Commercial-stage cell therapy company with approved autologous cell therapy products; comparable to PharmaCyte in the broader cell therapy space, though further along the regulatory and commercialization curve.

Emerging players

• Cytori Therapeutics: Cell therapy company developing autologous cell-based therapeutics; comparable to PharmaCyte in leveraging cellular encapsulation/delivery approaches across multiple disease areas.

Others

• Austrianova (SG Austria): Manufacturing partner for PharmaCyte's encapsulated cell products; directly relevant as the core enabler of PharmaCyte's Cell-in-a-Box technology and a cGMP production capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/PharmaCyte
• YouTubeyoutube.com/channel/UCTTLWMRaTZPRsIIRJmgqzhg
• Facebookfacebook.com/pharmacytebiotech
• LinkedInlinkedin.com/company/pharmacyte-biotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PMCB LTD